Nasdaq Moves to Delist MEDIROM After Missed Filing Deadline; Appeal Filed
MRM is trading near its 52-week low of $0.245 (6.6% above the low) on light trading volume (0.1× avg).
Summary
Nasdaq issued a delisting determination on November 13 after MEDIROM failed to file its FY2025 20-F within the extension period previously granted, meaning the company did not regain compliance with Listing Rule 5250(c)(1). ADSs would be suspended and delisted at the open on November 24, 2026 unless the company appealed. MEDIROM filed the overdue 20-F today — the same filing that disclosed a JPY3.6 billion net loss, substantial going-concern doubt and unremedied issues — and submitted a hearing request the same day, which automatically stays any suspension for 15 days; it has asked for an extended stay through the hearing process. The filing does not fix the separate minimum bid price deficiency flagged October 6, where the stock at $0.26 sits far below the $1.00 threshold and the company has until April 5, 2027 to cure it. With a micro-cap valuation and a going-concern warning in the annual report, the appeal is the only thing standing between the ADSs and a suspension two weeks out. Nasdaq's response to the 20-F filing and the scheduling of the hearing are the next hard checkpoints.
At the time of this announcement, MRM was trading at $0.26 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.25 to $2.33. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.